cefpiramide and Genital-Diseases--Female

Cefpiramide (SM-1652, CPM), a new cephem antibiotic was studied for the transfer into intrapelvic tissues and clinical efficacy in the field of obstetrics and gynecology. The results were obtained as follows. Clinical results of 17 patients with obstetrical and gynecological infection were excellent in 10 cases, good in 6, and poor in 1 with the efficacy rate of 94.1%. Following a single intravenous 30 minutes-drip infusion of 1 g dose of CPM, the peak of serum level and intrapelvic tissues were obtained at 30-60 minutes after completion of the administration. No adverse reaction or abnormal laboratory findings were observed.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Endometritis; Escherichia coli; Female; Genital Diseases, Female; Humans; Kinetics; Middle Aged; Pregnancy; Puerperal Infection; Uterus

Fundamental and clinical studies on a new cephalosporin antibiotic, cefpiramide (CPM), was carried out under a joint study program, in order to evaluate the usefulness of the drug in treating infection of the female genital organs. The results obtained were as follows: CPM was readily transported to female genital organ tissues, and the concentrations of the drug exceeded 35 micrograms/g in various organ tissues in about 1 hour, following intravenous injection of 1 g. A level of more than 2 micrograms/g was maintained even 14 hours after the injection. The transport of CPM to various tissues was also studied following intravenous drip infusion of 1 g for 1 hour. The concentrations in tissues were slightly low but similar to those following intravenous injection. The peak concentration of the drug in the dead space exudate was 3.1-20.4 micrograms/ml, following intravenous injection and intravenous drip infusion of 1 g. The MIC80 of CPM were 3.13-12.5 micrograms/ml against S. aureus, Klebsiella sp., P. mirabilis and P. aeruginosa. Clinical effects of CPM were analyzed in 158 patients, including 56 cases with intrauterine infection, 37 cases with intrapelvic infection, 22 cases with external genital infection, 31 cases with adnexitis, 6 cases with postoperative wound infection and 6 cases with other infections. Excellent response was seen in 28 cases (17.7%), good response in 120 (75.9%) poor response in 10 (6.3%). The rate of response was calculated as 93.7%. Safety of the drug was analyzed in 258 patients, and side effects occurred in 4 (1.6%). Of these 4 patients, rash was in 1 patient, heat sensation in 1 patient, nausea in 1 patient and rash accompanying edema in 1 patient. Abnormal values in clinical laboratory findings were seen in 7 patients. Elevations of transaminase were seen in 5 patients and decrease of platelet was seen in a patient, and then elevations of transaminase with decrease of platelet was seen in a patient, and no other changes of particular note appeared.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Genital Diseases, Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Infusions, Parenteral; Injections, Intravenous; Kinetics; Middle Aged; Uterus

In vivo transfer and therapeutic efficiency of a new cephalosporin derivative, cefpiramide (CPM) have studied in perinatal and gynecologic field. The following results have been obtained. The level of CPM transferred to uterus and adnexa was higher than its MIC against majority of Gram-negative bacilli, such as E. coli. This drug as demonstrated its efficiency, in treating 3 infection cases refractory to cephalothin, ampicillin and cephalexin, out of which 1 had "excellent" and 2 had "good" results. No side effect was evidenced in any of our patients. In conclusion, this drug has satisfactory tissue transfer as well as sufficient safety and excellent efficiency in treatment of perinatal infection cases.

Topics: Adnexa Uteri; Adult; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Fetal Membranes, Premature Rupture; Genital Diseases, Female; Humans; Hysterectomy; Kinetics; Pregnancy; Uterus

Clinical study on cefpiramide (CPM, SM-1652), a new cephalosporin antibiotic, was carried out and the following results were obtained. CPM was intravenously administrated at a daily dose of 2 g to 8 cases including 2 cases with intrauterine infection, 3 cases with adnexitis, 2 cases with intrapelvic infection and 1 case with external genital infection. All cases responded to the drug, and marked response was seen in 2 cases, moderate response in 6 cases. Neither side effects nor abnormal values in clinical laboratory findings attributable to the drug were seen.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Fetal Membranes, Premature Rupture; Genital Diseases, Female; Humans; Hysterectomy; Middle Aged; Pregnancy

Transfer of cefpiramide (SM-1652, CPM) to female genital organs was studied. CPM concentration was determined in the uterine artery, portio vaginalis, myometrium, ovary and oviduct of patients undergoing hysterectomy, and in the pelvic dead space exudate of patients undergoing radical hysterectomy due to uterocervical cancer. Data obtained were analyzed by three-compartment model. The maximum concentration at 1 hour after intravenous drip infusion of CPM in a dose of 1 g were 244.31 micrograms/ml in both the uterine arterial serum and uterine venous serum, 31.41 micrograms/g in the portio vaginalis, 32.99 micrograms/g in the myometrium, 31.67 micrograms/g in the ovary and 31.99 micrograms/g in the oviduct. The concentration in the pelvic dead space exudate reached to the maximum level of 5.32 micrograms/ml at 5.84 hours and thereafter decreased slowly. The clinical effect of CPM was examined in 6 patients with various female genital infections and found to be effective in all cases. Side effects and abnormal laboratory finding values were not observed at all.

Topics: Adnexa Uteri; Adult; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Genital Diseases, Female; Gram-Negative Bacteria; Humans; Kinetics; Middle Aged; Pelvis; Uterus

Fundamental and clinical studies of cefpiramide (CPM, SM-1652) a new semisynthetic cephalosporin were carried out in the field of obstetrics and gynecology. The results were obtained as follows: In vitro antibacterial activity of CPM against recent 255 clinical isolates was compared with those of cefazolin (CEZ), cefmetazole (CMZ) and cefoperazone (CPZ). CPM showed strong antibacterial activity against Staphylococcus, K. pneumoniae, Peptococcus and Peptostreptococcus. However the minimum inhibitory concentration of CPM was inferior to those of CEZ, CMZ and CPZ against E. coli. The transfer of CPM to the female genital organs was found to be good. Tissue levels over than 5 micrograms/g were maintained after 5 hours. CPM was administered to 10 patients with obstetrical and gynecological infections. Good responses were obtained in all of the cases. Neither adverse reactions nor abnormal laboratory findings were observed except 1 case with slight elevation of BUN.

Topics: Adult; Bacteria; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Genital Diseases, Female; Humans; Kinetics; Uterus

Cefpiramide (CPM) was evaluated for clinical effects in the treatment of obstetrical and gynecological infections. The following results were obtained. CPM was given to 11 cases. Clinical efficacy was good in 8 cases and poor in 3 cases. The poor cases were parametritis and pyometra from those Serratia sp., K. pneumoniae, P. magnus, E. faecalis and B. ovatus were isolated. Other 1 case was external genital abscess with no isolated bacteria. There was a slight transaminase elevation in 1 case but no other appreciable side effects or abnormal laboratory findings were observed.

Topics: Adolescent; Adult; Aged; Bacterial Infections; Cephalosporins; Drug Resistance, Microbial; Female; Genital Diseases, Female; Humans; Middle Aged; Pregnancy; Pregnancy Complications, Infectious

Cefpiramide (CPM, SM-1652), a new cephem antibiotic, was fundamentally and clinically studied. The following results were obtained. Serum and internal genital tissue levels of CPM were measured following intravenous drip infusion of 1 g. High serum levels of 30 micrograms/ml and tissue levels of more than 4 micrograms/g were at least maintained for 8 hours. Favourable transfer of CPM into the pelvic dead space exudate was observed. The exudate level was 7.25 micrograms/ml on average even at 8 hours after intravenous drip infusion. A total of 6 cases comprising 4 with Bartholin's cyst, 1 with pelvic peritonitis and 1 with lymphocyst was treated with CPM at a dose of 0.5-2 g twice daily by intravenous injection or intravenous drip infusion. The clinical response was excellent in 1 case and good in 5 cases. Side effects and abnormal laboratory findings due to the drug were not noted.

Topics: Adult; Bacterial Infections; Body Fluids; Cephalosporins; Drug Resistance, Microbial; Female; Genital Diseases, Female; Humans; Kinetics; Middle Aged; Pelvis; Peptostreptococcus; Staphylococcus epidermidis

Cefpiramide (CPM) was administrated intramuscularly to 27 cases of gynecological infections to evaluate its clinical efficacy and safety and the following results wee obtained. CPM was effective to all the cases of gynecological infections, and excellent was seen in 14 cases and good was seen in 13 cases. CPM eliminated 75% of clinical isolates. Laboratory tests were performed to blood samples and functions of liver and kidney before and after CPM treatment. Elevation of GPT was observed in 2 cases but required no treatment.

Topics: Adolescent; Adult; Bacteria, Anaerobic; Bacterial Infections; Cephalosporins; Drug Evaluation; Drug Resistance, Microbial; Endometritis; Female; Genital Diseases, Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Middle Aged; Pelvic Inflammatory Disease

A new cephalosporin, cefpiramide was administered to 12 patients with gynecological infections and the clinical effects obtained were good in 11 cases and poor in 1 (effective ratio: 91.7%). No side effects were observed except for eruption in 1 case, however, the relationship between the drug and eruption was unknown. No abnormalities were observed in hematological, hepatic and renal tests.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Evaluation; Drug Resistance, Microbial; Female; Genital Diseases, Female; Gram-Negative Bacteria; Humans; Injections, Intravenous; Middle Aged

Fundamental and clinical studies were performed on cefpiramide (CPM), a new cephem antibiotic, with following results. Following a single intravenous administration of 1.0 g dose of CPM, the average serum level of CPM was 129.5 micrograms/ml after 1 hour and the half-life in beta-phase was about 5.0 hours. The transfer of CPM to the internal genital organs was found to be good. the transfer of CPM to retroperitoneal fluid was moderate. In clinical trial, CPM was given to 9 patients with obstetrical and gynecological infection. Efficacy was excellent in 1 case and good in 6 cases (effectiveness rate: 77.8%). No side effects were observed. In laboratory findings, a mild elevation of S-GOT was noted in 1 case.

Topics: Adult; Aged; Bacterial Infections; Cephalosporins; Drug Evaluation; Female; Genital Diseases, Female; Genitalia, Female; Humans; Middle Aged; Pelvis